

---



**Supplementary information**

---

**Biopharma dealmaking in 2020**

---

In the format provided by the authors

**a****b**

**Fig. S1 | Distribution of the 19 M&A deals in 2020 worth  $\geq$ US\$1 billion by target focus.**  
**a** | Distribution by M&A deal volume. **b** | Distribution by M&A deal value.




Fig. S2 | **Breakdown of 2020 COVID-19 partnerships by drug type.**

Supplementary Table 1 | **2020 M&As featuring COVID-19 assets**

Month	Acquirer	Target	COVID-19 asset	Deal value (US\$ millions)
November	Merck & Co.	OncoImmune	Phase III recombinant fusion protein CD24Fc for COVID-19 patients requiring oxygen support	425
November	Sanofi	Kiadis	Natural killer cell therapy KNK-ID-101, potential post-exposure pre-emptive therapy	359
May	Novavax	Praha Vaccines	150k square foot facility to produce antigen doses for Novavax's COVID-19 vaccine NVX-CoV2373	167
November	MyMD Pharmaceuticals	Akers Biosciences	COVID-19 vaccine candidate partnered with Premas Biotech	80
October	4D Pharma	Longevity	Phase II live biotherapeutic MRx-4DP0004	38
July	Sorrento	SmartPharm	Non-viral DNA and RNA gene delivery platforms for COVID-19	19
September	Orgenesis	Koligo Therapeutics and Tissue Genesis	Autologous cell therapy KT-PC-301 COVID-19-related acute respiratory disease syndrome	16
May	Oragenics	Noachis Terra	TerraCoV2 vaccine candidate	2
May	Kalytera	Salzman Group	R-107, a liquid pro-drug of nitric oxide, for COVID-19 associated lung disease	na
May	BetterLife Pharma	Altum	Inhalable interferon a2b AntiCovir (AP-003)	na
May	Merck & Co.	Themis Bioscience	Measles virus vector platform used for COVID-19 vaccines	na
September	Emergex Vaccines	ImmProNano	CRO that has existing work with Emergex, including preclinical testing of COVID-19 vaccine	na
October	Cytocom	Cleveland BioLabs	Phase II CYTO-205 based on advanced immunomodulating multi-receptor system (AIMS) platform	na
December	ImmunityBio	NantWest	Several candidates, through prior partnership, to prevent and treat SARS-CoV-2, including "haNK" natural killer cells, mesenchymal stem cells, adenovirus constructs, and N-803, an IL-15 cytokine superagonist	na